Cargando…

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes

BACKGROUND: We previously reported the effect of sitagliptin or glimepiride treatment for 24 weeks on body composition in Japanese overweight and obese patients with type 2 diabetes. Although the degree of HbA1c reduction was similar between the two groups, significant reduction of intrahepatic lipi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishii, Satoshi, Nagai, Yoshio, Kato, Hiroyuki, Fukuda, Hisashi, Tanaka, Yasushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011940/ https://www.ncbi.nlm.nih.gov/pubmed/32095182 http://dx.doi.org/10.14740/jocmr4078

Ejemplares similares

Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series
por: Ishii, Satoshi, et al.
Publicado: (2019)

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy
por: Nagai, Yoshio, et al.
Publicado: (2019)

Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase‐4 inhibitor
por: Maita, Hiroki, et al.
Publicado: (2021)

Nature of action of Sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals
por: Davis, Joseph A., et al.
Publicado: (2010)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
por: Kubota, Yoshiaki, et al.
Publicado: (2012)

Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin
por: Wilson, Jessica R., et al.
Publicado: (2017)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
por: Mega, Cristina, et al.
Publicado: (2017)

Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
por: Nagai, Yoshio, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells
por: Komatsu, Tomohiro, et al.
Publicado: (2023)

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
por: Masuda, Daisaku, et al.
Publicado: (2018)

Macrocarpal C isolated from Eucalyptus globulus inhibits dipeptidyl peptidase 4 in an aggregated form
por: Kato, Eisuke, et al.
Publicado: (2017)

Endogenous dipeptidyl peptidase IV modulates skeletal muscle arteriolar diameter in rats
por: Neidert, Leslie E., et al.
Publicado: (2018)

Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”
por: Wilson, Jessica R, et al.
Publicado: (2020)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice
por: Li, Jingjing, et al.
Publicado: (2014)

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice
por: Zheng, Wenbin, et al.
Publicado: (2018)

Correction: Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
por: Lim, Soo, et al.
Publicado: (2012)

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
por: Naimi, Rahim Mohammad, et al.
Publicado: (2021)

Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma
por: Harada, Masaru, et al.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitor: Sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats
por: Rofaeil, Remon Roshdy, et al.
Publicado: (2022)

Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
por: Kitagawa, Noriyuki, et al.
Publicado: (2018)

The Dipeptidyl Peptidase-4 Inhibitor Des-Fluoro-Sitagliptin Regulates Brown Adipose Tissue Uncoupling Protein Levels in Mice with Diet-Induced Obesity
por: Shimasaki, Takanobu, et al.
Publicado: (2013)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
por: Nakaoku, Yuriko, et al.
Publicado: (2019)

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study
por: Solis-Herrera, Carolina, et al.
Publicado: (2013)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Effect of Ezetimibe Monotherapy on Low-Density Lipoprotein Cholesterol and on Markers of Cholesterol Synthesis and Absorption in Japanese Patients With Hypercholesterolemia
por: Ohta, Akio, et al.
Publicado: (2017)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
por: Barchetta, Ilaria, et al.
Publicado: (2022)

Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4(+) T-Cell Migration Through Incretin-Dependent and -Independent Pathways
por: Kim, Su-Jin, et al.
Publicado: (2010)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
por: Tong, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4ke8a7lg91t51v6sac4vcfigea